Company news
Actuate Therapeutics, Inc. news in 2026
Actuate Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
November 18, 2026
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
November 4, 2026
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
November 2, 2026
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
October 27, 2026
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
June 8, 2026
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
May 31, 2026
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 10, 2026
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
May 6, 2026
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
April 13, 2026
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
March 8, 2026
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
March 4, 2026
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 24, 2026
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
January 21, 2026
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
January 12, 2026
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO...
January 11, 2026
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
January 6, 2026
Decks in 2026
- Investor Presentation (November 2026)
Investor deck · 16 slides · November 2026
- Investor Presentation (September 2026)
Investor deck · 17 slides · September 2026
- Investor Presentation (May 2026)
Investor deck · 18 slides · May 11, 2026
- Investor Presentation (January 2026)
Investor deck · 34 slides · January 2026